TAKEDA PHARMACEUTICAL CO LTD (TAK)
About TAKEDA PHARMACEUTICAL CO LTD
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $49.3B
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $49.3B
- Dividend yield
- 3.58%
- Shares outstanding
- 2.9B
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 7, 2008
Takeda Pharmaceutical Co Ltd (TAK) Stock Price
- Trading 8% below its 52-week high.
- Pays a dividend yielding about 3.58% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review TAKEDA PHARMACEUTICAL CO LTD.
Write a review
News about TAKEDA PHARMACEUTICAL CO LTD
News & sentiment via Polygon.io
Takeda Pharmaceutical Co Ltd: frequently asked questions
Is Takeda Pharmaceutical Co Ltd an American company?
Takeda Pharmaceutical Co Ltd is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Takeda Pharmaceutical Co Ltd publicly traded?
Yes — Takeda Pharmaceutical Co Ltd is a publicly traded company. Its stock trades under the ticker symbol TAK on the NYSE.
What does Takeda Pharmaceutical Co Ltd do?
Takeda Pharmaceutical Co Ltd is an American Pharmaceuticals company in the Health & Beauty sector.
